Literature DB >> 7468760

The effects of heparin treatment on hypertension and vascular lesions in stroke-prone spontaneously hypertensive rats.

S K Wilson, K Solez, J K Boitnott, R H Heptinstall.   

Abstract

Stroke-prone spontaneously hypertensive rats (SPSHRs) were used to test the theory that heparin treatment may prevent the development of "malignant" hypertension and fibrinoid vascular lesions in the kidney. Subcutaneous injections of heparin (100 units/100 g body weight) were given every 8 hours over a 5-week period to 12 young (10-week-old) SPSHRs. A control group of 12 SPSHRs was injected with saline. Both heparin-treated and control animals showed an incremental rise in mean systolic pressure, but the pressure was significantly lower (P less than 0.05) in the heparin-treated animals during weeks 1-4 of treatment. There were significantly fewer fibrinoid vascular lesions (P less than 0.03) in the heparin-treated group. In 7 additional heparin-treated and 7 control SPSHRs plasma and blood volumes were determined for assessment of the effects of heparin treatment. There was no significant difference in total blood volume or plasma volume between the two groups, but heparin-treated animals had lower hematocrit levels. In 8 SPSHRs direct arterial pressures were recorded for 1 hour after a single heparin injection, and no acute changes in blood pressure were observed. The results suggest that heparin treatment prevents the development of severe fibrinoid vascular lesions and also attenuates the rate of the rise in systolic blood pressure; moreover, this reduction in blood pressure is not caused by a significant reduction in blood volume or an acute hypotensive effect of heparin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7468760      PMCID: PMC1903448     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  27 in total

1.  THE PATHOGENIC ROLE OF THE COAGULATION PROCESS IN RABBIT MASUGI NEPHRITIS.

Authors:  P VASSALLI; R T MCCLUSKEY
Journal:  Am J Pathol       Date:  1964-10       Impact factor: 4.307

2.  PROTECTIVE ACTION OF HEPARIN IN EXPERIMENTAL IMMUNE NEPHRITIS.

Authors:  B HALPERN; P MILLIEZ; G LAGRUE; A FRAY; J C MORARD
Journal:  Nature       Date:  1965-01-16       Impact factor: 49.962

3.  The circulatory effects of hematocrit variations in normovolemic and hypervolemic dogs.

Authors:  J F MURRAY; P GOLD; B L JOHNSON
Journal:  J Clin Invest       Date:  1963-07       Impact factor: 14.808

4.  Studies in intravascular coagulation. IV. The effect of heparin and dicumarol on serum-induced venous thrombosis.

Authors:  S WESSLER; L E MORRIS
Journal:  Circulation       Date:  1955-10       Impact factor: 29.690

5.  Cardiac hypertrophy in experimental hypertension and its regression following reestablishment of normal blood pressure.

Authors:  O HALL; C E HALL; E OGDEN
Journal:  Am J Physiol       Date:  1953-07

Review 6.  Pharmacodynamics and clinical effectiveness of heparin.

Authors:  L B Jaques; J Mahadoo
Journal:  Semin Thromb Hemost       Date:  1978       Impact factor: 4.180

7.  Modification of the vascular lesions of rejection in cadaveric renal allografts by dipyridamole and anticoagulants.

Authors:  P Kincaid-Smith
Journal:  Lancet       Date:  1969-11-01       Impact factor: 79.321

8.  Genetic predisposition to stroke in spontaneously hypertensive rats.

Authors:  A Nagaoka; H Iwatsuka; Z Suzuoki; K Okamoto
Journal:  Am J Physiol       Date:  1976-05

9.  Disseminated intravascular coagulation induced by Liquoid in the rat. II. Effect of heparin on hematologic and complement abnormalities and renal lesions studied by light, fluorescence, and electron microscopy.

Authors:  R E Urizar; G Sherer; A Tartaglia; R J Pickering; W J Dodds
Journal:  Lab Invest       Date:  1976-05       Impact factor: 5.662

Review 10.  Heparin: an old drug with a new paradigm.

Authors:  L B Jacques
Journal:  Science       Date:  1979-11-02       Impact factor: 47.728

View more
  7 in total

1.  Glomerular endothelial cells secrete a heparinlike inhibitor and a peptide stimulator of mesangial cell proliferation.

Authors:  J J Castellot; R L Hoover; M J Karnovsky
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

2.  Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells.

Authors:  K Yokokawa; H Tahara; M Kohno; A K Mandal; M Yanagisawa; T Takeda
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

3.  The effects of heparin treatment on vascular permeability and vessel wall damage in acute hypertension in the rat.

Authors:  S K Wilson; R H Heptinstall
Journal:  Am J Pathol       Date:  1983-06       Impact factor: 4.307

Review 4.  Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension.

Authors:  G H Gibbons; V J Dzau
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

5.  Hypotensive effect of heparin on experimental chronic pulmonary hypertension in rats.

Authors:  D Kentera; D Susić; M Zdravković
Journal:  Basic Res Cardiol       Date:  1985 Mar-Apr       Impact factor: 17.165

6.  Heparin inhibits mesangial cell proliferation in habu-venom-induced glomerular injury.

Authors:  A K Coffey; M J Karnovsky
Journal:  Am J Pathol       Date:  1985-08       Impact factor: 4.307

7.  Heparin and glomerular epithelial cell-secreted heparin-like species inhibit mesangial-cell proliferation.

Authors:  J J Castellot; R L Hoover; P A Harper; M J Karnovsky
Journal:  Am J Pathol       Date:  1985-09       Impact factor: 4.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.